Ixekizumab and newer therapies for plaque psoriasis
Data presented on ixekizumab relating to its fast onset of efficacy, superiority in head-to-head trials, to ustekinumab, guselkumab and adalimumab in psoriatic arthritis
You will learn:
• To understand the impact of psoriasis on a patient’s quality of life (QoL)
• To interpret how to use newer biologics in terms of the pathogenesis of psoriasis
• To evaluate the latest clinical data on the use of ixekizumab (IXE) in order to prioritise patients who will benefit from this newer therapy
WEBINAR HELD ON 30 JANUARY 2023.